Cempra, Inc. (CEMP)

[agamemnus]

I bet the chief dish washer knows a lot! They must pay them well so that they keep those secrets, secrets.

I suppose you have possibly read my newest article on SA?

Agreed that they have everything here that they need to make a formidable company; Baxdela and solithromycin have a lot of potential.

Baxdela is the only fluoroquinolone to be approved for ABSSSI -- as far as I know. And fluoroquinolones (FQs) are known for two things:

(1) Tendon rupture. 2014: 21 confirmed cases of "FQ-associated disability" (https://en.wikipedia.org/wiki/Fluoroquinolone-associated_disability) out of 32.8m oral FQ prescriptions. That's pretty rare, though. But most also have QT prolongation, which Baxdela doesn't have. And it is very different from many other FQs.... so who knows.


(2) Their extreme potency. Baxdela is especially potent here in methicillin resistant Staphulococcus aureus, which is a big thing:

MT @jcederholm: Prevalence of #AMR in the @WHO European Region #MRSA #AntibioticResistance @WHO_Europe pic.twitter.com/f76H7oWLGc

— Melinta Therapeutics (@MelintaTx) July 14, 2015

.

And then there is Taksta (old but will generate revenue since not available in US), radezolid, and oxazolidinone....
A lot of possibilities.